トリプルネガティブ乳がんの世界市場レポート 2025年

トリプルネガティブ乳がん市場規模は、今後数年間で力強い成長が見込まれます。2029年には5.7%の複合年間成長率（CAGR）で9億5,000万米ドルに成長します。予測期間の成長は、乳がん症例の増加、トリプルネガティブ乳がんの罹患率の増加、ヘルスケアインフラの拡大、研究開発活動の増加、HER2陽性乳がんの症例の増加などに起因すると考えられます。この期間の主な動向としては、革新的なTNBC治療、放射線技術の進歩、診断技術の向上、個別化医療に対する需要の増加、継続的な製品革新などが挙げられます。

ヘルスケア施設の進歩がトリプルネガティブ乳がん（TNBC）市場の成長を促進すると予想されます。病院、診療所、診断センターなどのヘルスケア施設は、患者に医療とサービスを提供します。ヘルスケアインフラの改善は、投資の増加、患者中心のケアの重視、人口増加、人口動態の高齢化に起因します。強化されたヘルスケア施設は、高度な診断技術、個別化治療、集学的ケアチーム、患者教育の改善へのアクセスを提供することによりTNBC治療をサポートし、早期発見、治療結果、生存率の向上につながります。例えば、2023年5月、米国医療協会は、米国の病院数が前年の6,093から6,129へと0.591％増加したと報告しました。その結果、医療施設の充実がTNBC市場の成長を後押ししています。

TNBC市場の主要企業は、がん治療の特異性と有効性を向上させるため、低分子医薬品などの革新的治療法の開発に注力しています。低分子医薬品は、細胞に浸透して生物学的プロセスを調節できる低分子化合物であり、がんやその他の疾患に対して有効です。例えば、米国を拠点とする臨床段階のバイオテクノロジー企業であるランタン・ファーマ社は、2024年12月、TNBC治療のための治験薬候補LP-184を発表しました。米国食品医薬品局（FDA）は、DNA損傷修復経路に特定のバイオマーカーや変異を持つがん細胞のDNAを選択的に損傷するように設計された次世代アシルフルベンと低分子薬剤であるLP-184をファストトラック指定しました。ランタン社独自のRADR AIプラットフォームは、本治療が奏効する可能性の高い患者集団やがんサブタイプの同定に役立ちます。LP-184は現在、複数の固形がんで評価されており、ナノモルの効力が実証され、薬剤耐性がんでの有望性が示され、標的がん治療を前進させる。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- マクロ経済シナリオ金利、インフレ、地政学、新型コロナウイルス感染症の影響と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界トリプルネガティブ乳がんPESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界のトリプルネガティブ乳がん市場：成長率分析
• 世界のトリプルネガティブ乳がん市場の実績：規模と成長, 2019-2024
• 世界のトリプルネガティブ乳がん市場の予測：規模と成長, 2024-2029, 2034F
• 世界トリプルネガティブ乳がん総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界のトリプルネガティブ乳がん市場治療の種類別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 化学療法
• 免疫療法
• 標的療法
• 手術
• 放射線治療
• その他の治療の種類
• 世界のトリプルネガティブ乳がん市場テストの種類別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 画像技術
• アッセイ
• 乳房生検
• 世界のトリプルネガティブ乳がん市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• 専門クリニック
• 外来手術センター
• その他のエンドユーザー
• 世界のトリプルネガティブ乳がん市場化学療法の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• アントラサイクリン系化学療法
• タキサン系化学療法
• プラチナ製剤化学療法
• 世界のトリプルネガティブ乳がん市場免疫療法の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• チェックポイント阻害剤
• がんワクチン
• 世界のトリプルネガティブ乳がん市場標的療法の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• PARP阻害剤
• VEGF阻害剤
• CDK4またはCDK6阻害剤
• 世界のトリプルネガティブ乳がん市場、手術の種類別の細分化、実績と予測, 2019-2024, 2024-2029F, 2034F
• 乳房切除術
• 乳房切除術
• リンパ節郭清
• 世界のトリプルネガティブ乳がん市場放射線治療の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 外部ビーム照射
• 近接放射線療法
• 世界のトリプルネガティブ乳がん市場、その他の治療タイプのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• ホルモン療法
• 温熱療法
• 幹細胞療法

第7章 地域別・国別分析

• 世界のトリプルネガティブ乳がん市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界のトリプルネガティブ乳がん市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• トリプルネガティブ乳がん市場：競合情勢
• トリプルネガティブ乳がん市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Bayer AG Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Bristol-Myers Squibb Company
• AstraZeneca Plc
• Novartis AG
• Fresenius Kabi AG
• GlaxoSmithKline plc
• Eli Lilly and Company
• Amgen Inc.
• Takeda Pharmaceutical Company Limited
• Gilead Sciences Inc.
• Astellas Pharma Inc.
• Daiichi Sankyo Company Limited
• Illumina Inc.
• Bio-Rad Laboratories Inc.
• Seagen Inc.
• MacroGenics Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• トリプルネガティブ乳がん市場2029：新たな機会を提供する国
• トリプルネガティブ乳がん市場2029：新たな機会を提供するセグメント
• トリプルネガティブ乳がん市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Triple-negative breast cancer (TNBC) is an aggressive and rapidly growing subtype of breast cancer that lacks estrogen receptors (ER), progesterone receptors (PR), and human epidermal growth factor receptor 2 (HER2), making it unresponsive to hormonal therapies or HER2-targeted treatments. Compared to other breast cancer types, TNBC is more challenging to treat and has a higher recurrence rate. It is more prevalent in younger women, African American women, and individuals with BRCA1 mutations, highlighting its genetic predisposition.

The primary treatment options for TNBC include chemotherapy, immunotherapy, targeted therapy, surgery, radiation therapy, and other approaches. Chemotherapy works by using drugs to destroy cancer cells or inhibit their growth. Diagnosis involves various tests, such as imaging techniques, assays, and breast biopsies. These treatments and diagnostic methods are utilized by hospitals, specialty clinics, ambulatory surgical centers, and other healthcare facilities.

The triple-negative breast cancer market research report is one of a series of new reports from The Business Research Company that provides triple-negative breast cancer market statistics, including triple-negative breast cancer industry global market size, regional shares, competitors with a triple-negative breast cancer market share, detailed triple-negative breast cancer market segments, market trends and opportunities, and any further data you may need to thrive in the triple-negative breast cancer industry. This triple-negative breast cancer market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The triple negative breast cancer market size has grown strongly in recent years. It will grow from $0.72 billion in 2024 to $0.76 billion in 2025 at a compound annual growth rate (CAGR) of 6.1%. The growth in the historic period can be attributed to the rising number of women, increasing demand for TNBC treatments, greater awareness of early breast cancer detection, a growing patient population, and increased healthcare spending.

The triple negative breast cancer market size is expected to see strong growth in the next few years. It will grow to $0.95 billion in 2029 at a compound annual growth rate (CAGR) of 5.7%. The growth in the forecast period can be attributed to the rising cases of breast cancer, the growing incidence of triple-negative breast cancer, expanding healthcare infrastructure, increasing research and development activities, and the rising cases of HER2-positive breast cancer. Key trends during this period include innovative TNBC treatments, advancements in radiation techniques, improvements in diagnostic technology, increasing demand for personalized medicine, and ongoing product innovation.

The advancement of healthcare facilities is expected to drive the growth of the triple-negative breast cancer (TNBC) market. Healthcare facilities, including hospitals, clinics, and diagnostic centers, provide medical care and services to patients. Improvements in healthcare infrastructure result from increased investment, a focus on patient-centered care, population growth, and aging demographics. Enhanced healthcare facilities support TNBC treatment by offering access to advanced diagnostic technologies, personalized therapies, multidisciplinary care teams, and improved patient education, leading to better early detection, treatment outcomes, and survival rates. For example, in May 2023, the American Health Care Association reported that the number of hospitals in the United States increased by 0.591%, from 6,093 in the previous year to 6,129. As a result, the improvement of healthcare facilities is fueling the growth of the TNBC market.

Leading companies in the TNBC market are focused on developing innovative treatments, such as small molecule drugs, to improve the specificity and effectiveness of cancer therapies. Small molecule drugs are low molecular weight compounds capable of penetrating cells to modulate biological processes, making them effective against cancer and other diseases. For instance, in December 2024, Lantern Pharma Inc., a US-based clinical-stage biotechnology company, announced the investigational drug candidate LP-184 for TNBC treatment. The U.S. Food and Drug Administration (FDA) granted Fast Track designation for LP-184, a next-generation acylfulvene and small molecule drug designed to selectively damage DNA in cancer cells with specific biomarkers or mutations in DNA damage repair pathways. Lantern's proprietary RADR AI platform helps identify patient populations and cancer subtypes likely to respond to the treatment. LP-184 is currently being evaluated across multiple solid tumors and has demonstrated nanomolar potency, showing promise in drug-resistant cancers and advancing targeted cancer therapy.

In December 2024, Galera Therapeutics Inc., a US-based biopharmaceutical company, acquired Nova Pharmaceuticals Inc. to advance its clinical development efforts. This acquisition enables Galera to further explore its inhibitor's potential in treating TNBC. Nova Pharmaceuticals Inc. is a US-based clinical-stage biotechnology company specializing in developing novel treatments for triple-negative and metaplastic breast cancer.

Major players in the triple negative breast cancer market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Bayer AG, Bristol-Myers Squibb Company, AstraZeneca Plc, Novartis AG, Fresenius Kabi AG, GlaxoSmithKline plc, Eli Lilly and Company, Amgen Inc., Takeda Pharmaceutical Company Limited, Gilead Sciences Inc., Astellas Pharma Inc., Daiichi Sankyo Company Limited, Illumina Inc., Bio-Rad Laboratories Inc., Seagen Inc., MacroGenics Inc., Immutep Limited, G1 Therapeutics Inc., Galera Therapeutics Inc., HiberCell Inc., Infinity Pharmaceuticals Inc.

North America was the largest region in the triple negative breast cancer market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in triple-negative breast cancer report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the triple-negative breast cancer market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The triple-negative breast cancer market consists of revenues earned by entities by providing services such as diagnostic testing, biomarker analysis, drug development and genetic testing. The market value includes the value of related goods sold by the service provider or included within the service offering. The triple-negative breast cancer market also includes sales of genetic testing kits, companion diagnostic tests, radiopharmaceuticals and clinical trial drugs. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Triple Negative Breast Cancer Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on triple negative breast cancer market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for triple negative breast cancer ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The triple negative breast cancer market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Treatment Type: Chemotherapy; Immunotherapy; Targeted Therapy; Surgery; Radiation Therapy; Other Treatment Types
• 2) By Type Of Test: Imaging Techniques; Assays; Breast Biopsy
• 3) By End-User: Hospitals; Specialty Clinics; Ambulatory Surgical Centers; Other End-Users
• Subsegments:
• 1) By Chemotherapy: Anthracyclines-based Chemotherapy; Taxane-based Chemotherapy; Platinum-based Chemotherapy
• 2) By Immunotherapy: Checkpoint Inhibitors; Cancer Vaccines
• 3) By Targeted Therapy: PARP Inhibitors; VEGF Inhibitors; CDK4 Or CDK6 Inhibitors
• 4) By Surgery: Mastectomy; Lumpectomy; Lymph Node Dissection
• 5) By Radiation Therapy: External Beam Radiation; Brachytherapy
• 6) By Other Treatment Types: Hormone Therapy; Hyperthermia Therapy; Stem Cell Therapy
• Companies Mentioned: Pfizer Inc.; F. Hoffmann-La Roche Ltd.; Merck & Co. Inc.; AbbVie Inc.; Bayer AG
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Triple Negative Breast Cancer Market Characteristics

3. Triple Negative Breast Cancer Market Trends And Strategies

4. Triple Negative Breast Cancer Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Triple Negative Breast Cancer Growth Analysis And Strategic Analysis Framework

• 5.1. Global Triple Negative Breast Cancer PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Triple Negative Breast Cancer Market Growth Rate Analysis
• 5.4. Global Triple Negative Breast Cancer Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Triple Negative Breast Cancer Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Triple Negative Breast Cancer Total Addressable Market (TAM)

6. Triple Negative Breast Cancer Market Segmentation

• 6.1. Global Triple Negative Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Chemotherapy
• Immunotherapy
• Targeted Therapy
• Surgery
• Radiation Therapy
• Other Treatment Types
• 6.2. Global Triple Negative Breast Cancer Market, Segmentation By Type Of Test, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Imaging Techniques
• Assays
• Breast Biopsy
• 6.3. Global Triple Negative Breast Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Specialty Clinics
• Ambulatory Surgical Centers
• Other End-Users
• 6.4. Global Triple Negative Breast Cancer Market, Sub-Segmentation Of Chemotherapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Anthracyclines-based Chemotherapy
• Taxane-based Chemotherapy
• Platinum-based Chemotherapy
• 6.5. Global Triple Negative Breast Cancer Market, Sub-Segmentation Of Immunotherapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Checkpoint Inhibitors
• Cancer Vaccines
• 6.6. Global Triple Negative Breast Cancer Market, Sub-Segmentation Of Targeted Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• PARP Inhibitors
• VEGF Inhibitors
• CDK4 Or CDK6 Inhibitors
• 6.7. Global Triple Negative Breast Cancer Market, Sub-Segmentation Of Surgery, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Mastectomy
• Lumpectomy
• Lymph Node Dissection
• 6.8. Global Triple Negative Breast Cancer Market, Sub-Segmentation Of Radiation Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• External Beam Radiation
• Brachytherapy
• 6.9. Global Triple Negative Breast Cancer Market, Sub-Segmentation Of Other Treatment Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hormone Therapy
• Hyperthermia Therapy
• Stem Cell Therapy

7. Triple Negative Breast Cancer Market Regional And Country Analysis

• 7.1. Global Triple Negative Breast Cancer Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Triple Negative Breast Cancer Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Triple Negative Breast Cancer Market

• 8.1. Asia-Pacific Triple Negative Breast Cancer Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Triple Negative Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Triple Negative Breast Cancer Market, Segmentation By Type Of Test, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Triple Negative Breast Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Triple Negative Breast Cancer Market

• 9.1. China Triple Negative Breast Cancer Market Overview
• 9.2. China Triple Negative Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Triple Negative Breast Cancer Market, Segmentation By Type Of Test, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Triple Negative Breast Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Triple Negative Breast Cancer Market

• 10.1. India Triple Negative Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Triple Negative Breast Cancer Market, Segmentation By Type Of Test, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Triple Negative Breast Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Triple Negative Breast Cancer Market

• 11.1. Japan Triple Negative Breast Cancer Market Overview
• 11.2. Japan Triple Negative Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Triple Negative Breast Cancer Market, Segmentation By Type Of Test, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Triple Negative Breast Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Triple Negative Breast Cancer Market

• 12.1. Australia Triple Negative Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Triple Negative Breast Cancer Market, Segmentation By Type Of Test, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Triple Negative Breast Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Triple Negative Breast Cancer Market

• 13.1. Indonesia Triple Negative Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Triple Negative Breast Cancer Market, Segmentation By Type Of Test, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Triple Negative Breast Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Triple Negative Breast Cancer Market

• 14.1. South Korea Triple Negative Breast Cancer Market Overview
• 14.2. South Korea Triple Negative Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Triple Negative Breast Cancer Market, Segmentation By Type Of Test, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Triple Negative Breast Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Triple Negative Breast Cancer Market

• 15.1. Western Europe Triple Negative Breast Cancer Market Overview
• 15.2. Western Europe Triple Negative Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Triple Negative Breast Cancer Market, Segmentation By Type Of Test, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Triple Negative Breast Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Triple Negative Breast Cancer Market

• 16.1. UK Triple Negative Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Triple Negative Breast Cancer Market, Segmentation By Type Of Test, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Triple Negative Breast Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Triple Negative Breast Cancer Market

• 17.1. Germany Triple Negative Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Triple Negative Breast Cancer Market, Segmentation By Type Of Test, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Triple Negative Breast Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Triple Negative Breast Cancer Market

• 18.1. France Triple Negative Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Triple Negative Breast Cancer Market, Segmentation By Type Of Test, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Triple Negative Breast Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Triple Negative Breast Cancer Market

• 19.1. Italy Triple Negative Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Triple Negative Breast Cancer Market, Segmentation By Type Of Test, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Triple Negative Breast Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Triple Negative Breast Cancer Market

• 20.1. Spain Triple Negative Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Triple Negative Breast Cancer Market, Segmentation By Type Of Test, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Triple Negative Breast Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Triple Negative Breast Cancer Market

• 21.1. Eastern Europe Triple Negative Breast Cancer Market Overview
• 21.2. Eastern Europe Triple Negative Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Triple Negative Breast Cancer Market, Segmentation By Type Of Test, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Triple Negative Breast Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Triple Negative Breast Cancer Market

• 22.1. Russia Triple Negative Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Triple Negative Breast Cancer Market, Segmentation By Type Of Test, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Triple Negative Breast Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Triple Negative Breast Cancer Market

• 23.1. North America Triple Negative Breast Cancer Market Overview
• 23.2. North America Triple Negative Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Triple Negative Breast Cancer Market, Segmentation By Type Of Test, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Triple Negative Breast Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Triple Negative Breast Cancer Market

• 24.1. USA Triple Negative Breast Cancer Market Overview
• 24.2. USA Triple Negative Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Triple Negative Breast Cancer Market, Segmentation By Type Of Test, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Triple Negative Breast Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Triple Negative Breast Cancer Market

• 25.1. Canada Triple Negative Breast Cancer Market Overview
• 25.2. Canada Triple Negative Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Triple Negative Breast Cancer Market, Segmentation By Type Of Test, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Triple Negative Breast Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Triple Negative Breast Cancer Market

• 26.1. South America Triple Negative Breast Cancer Market Overview
• 26.2. South America Triple Negative Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Triple Negative Breast Cancer Market, Segmentation By Type Of Test, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Triple Negative Breast Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Triple Negative Breast Cancer Market

• 27.1. Brazil Triple Negative Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Triple Negative Breast Cancer Market, Segmentation By Type Of Test, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Triple Negative Breast Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Triple Negative Breast Cancer Market

• 28.1. Middle East Triple Negative Breast Cancer Market Overview
• 28.2. Middle East Triple Negative Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Triple Negative Breast Cancer Market, Segmentation By Type Of Test, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Triple Negative Breast Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Triple Negative Breast Cancer Market

• 29.1. Africa Triple Negative Breast Cancer Market Overview
• 29.2. Africa Triple Negative Breast Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Triple Negative Breast Cancer Market, Segmentation By Type Of Test, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Triple Negative Breast Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Triple Negative Breast Cancer Market Competitive Landscape And Company Profiles

• 30.1. Triple Negative Breast Cancer Market Competitive Landscape
• 30.2. Triple Negative Breast Cancer Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Bayer AG Overview, Products and Services, Strategy and Financial Analysis

31. Triple Negative Breast Cancer Market Other Major And Innovative Companies

• 31.1. Bristol-Myers Squibb Company
• 31.2. AstraZeneca Plc
• 31.3. Novartis AG
• 31.4. Fresenius Kabi AG
• 31.5. GlaxoSmithKline plc
• 31.6. Eli Lilly and Company
• 31.7. Amgen Inc.
• 31.8. Takeda Pharmaceutical Company Limited
• 31.9. Gilead Sciences Inc.
• 31.10. Astellas Pharma Inc.
• 31.11. Daiichi Sankyo Company Limited
• 31.12. Illumina Inc.
• 31.13. Bio-Rad Laboratories Inc.
• 31.14. Seagen Inc.
• 31.15. MacroGenics Inc.

32. Global Triple Negative Breast Cancer Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Triple Negative Breast Cancer Market

34. Recent Developments In The Triple Negative Breast Cancer Market

35. Triple Negative Breast Cancer Market High Potential Countries, Segments and Strategies

• 35.1 Triple Negative Breast Cancer Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Triple Negative Breast Cancer Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Triple Negative Breast Cancer Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer